3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Terminated
4
Recruiting
3
Completed
3
Suspended
1
Sponsor Class
INDUSTRY
3
OTHER
2
NIH
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Non-Small-Cell Lung
429
Breast Neoplasms
298
Neoplasms
296
Colorectal Neoplasms
242
Neoplasm Metastasis
197
Ovarian Neoplasms
171
Lung Neoplasms
150
Recurrence
147
Prostatic Neoplasms
146
Pancreatic Neoplasms
142
Multiple Myeloma
136
Stomach Neoplasms
129
Squamous Cell Carcinoma of Head and Neck
128
Melanoma
123
Leukemia, Myeloid, Acute
115
Endometrial Neoplasms
115
Advanced Solid Tumors
113
Advanced Solid Tumor
108
Carcinoma, Hepatocellular
102
Triple Negative Breast Neoplasms
101
Small Cell Lung Carcinoma
88
Uterine Cervical Neoplasms
86
Lymphoma, Non-Hodgkin
83
Carcinoma, Renal Cell
72
Lymphoma, Follicular
71
Lymphoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
65
Solid Tumor
64
Lymphoma, Large B-Cell, Diffuse
64
Hematologic Neoplasms
62
Interventions
abiraterone
2
enzalutamide
1
darolutamide
1
Prednisolone
1
Docetaxel
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Bulbo-Spinal Atrophy, X-Linked
×
Clear all
NCT07190300
2026-06-03
TulmiSTAR-02
Novartis
Phase 1/2
Recruiting
181 enrolled
NCT06764485
2026-05-06
rechARge
Celgene
Phase 3
Recruiting
960 enrolled
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled